Abstract
Background: Atrial fibrillation (AF) is the most common arrhythmia type. The prevalence of AF is associated with different factors such as age, body mass index (BMI), physical activity, genetic factors and lifestyle factors. AF is associated with an increased risk of stroke and embolic events. Treatment guidelines recommend the combination of anticoagulant and rate control with rhythm control for highly symptomatic patients.
Aim: To evaluate the knowledge, attitude, and barriers of family physicians to use oral anticoagulation in arterial fibrillation.
Methods: This study is a cross sectional study which was conducted in 4 hospitals and 8 primary care centers at Riyadh, Saudi Arabia, on family physicians. The study used pre-designed questionnaire which involved questions about demographics, knowledge, attitude and barriers.
Results: There were 52 physicians had average awareness about practice guidelines, 27 had good awareness, 4 had excellent awareness, 17 and 14 had fair and poor awareness respectively. The overall knowledge was significantly associated with job position, where consultants had higher mean knowledge. The most common barriers were lack of follow-up system and lab investigations.
Conclusion: There was positive attitude with moderate overall knowledge, it is recommended to increase knowledge by establishing educational program and it is necessary to provide follow-up system and facilitate performing of lab investigations to decrease parries and facilitate practice of use of anti-coagulants.
Keywords: AF, Oral anticoagulants, Family physicians, knowledge of anticoagulants, attitude of anticoagulants, anticoagulants barriers.
References
- Greenlee RT and Vidaillet H. Recent progress in the epidemiology of atrial fibrillation. Curr Opin Cardiol. 2005; 20(1):7-14.
- Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8): 837–47.
- Al-Harbi and Al-Suhaibani M. The prevalence of atrial fibrillation among adult Saudi patients with chronic heart failure at Prince Sultan Cardiac Center, Qassim (2011–2014). Hamdan Medical Journal 2015; 8(Suppl. 1):201–202.
- Sankaranarayanan R, Kirkwood G, Dibb K and Garratt CJ. Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review. Cardiology Research and Practice;2013.
- Dalmau GM, Arderiu ES, Montes MBE, SolàI, Saco SP and Coello PA. Patients’and physicians’perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Family Practice; 2017:18:3.
- Wolf PA, Abbott RD and Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22:983–988.
- Hersi A, Abdul-Moneim M, Almous’ad A, Al-Samadi F, AlFagih A and Sweidan R. Saudi Atrial Fibrillation Survey: National, Observational, Cross-sectional Survey Evaluating Atrial Fibrillation Management and the Cardiovascular Risk Profile of Patients With Atrial Fibrillation. Angiology; 2015: 66(3) 244-248.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med; 2011:365:883-91.
- The Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med1994;154:1449–1457.
- Gustafsson C, Blomback M, Britton M, Hamsten A and Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990;21:47–51.
- Buckingham TA and Hatala Anticoagulants for Atrial Fibrillation: Why Is the Treatment Rate So Low?. Clin. Cardiol; 2002:25:447–454
- Fuster V, Ryden LE, Caimom DS, et al. ACC/AHA/ESC 2006. Guidelines for the management of patients with atrial fibrillation. A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines: developed in collaboration with the European heart rhythm association and the heart rhythm society. Circulation. 2006;114(7):257-354.
- Snow V, Weiss KB, Le Fevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American academy of family physicians and the American college of physicians. Ann Intern Med; 2003:139(12):1009-1017.
- Nicholls SG, Brehaut JC, Arim RG, Carroll K, Perez R, Shojania KG et al. Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians. Thrombosis Journal; 2014:12:13.
- Boysen G, Connolly S, Esekowitz M, Hart R, James K, Kistler P, et al. Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med; 1994:154(13):1449–57.
- Hart RG, Pearce LA andAguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with thespecial contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016 Aug 27.
- January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, et al, ACC/AHA Task Force Members. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
- Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet; 2014;383(9921):955–62.
- Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA and Joyner C.Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349–355.
- Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med1992;327:1406–1412.
- The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med; 1990:323:1505–1511
- Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527–539.
- Stroke Prevention in Atrial Fibrillation III randomised clinical trial: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet; 1996;348:633–638
- Hart RG, Benavente O and Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis1999;9:215–217
- Pugh D, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011; 40: 675–83.
- Anderson N, Fuller R and Dudley N. ‘Rules of thumb’or reflective practice? Understanding senior physicians’decision-making about anti-thrombotic usage in atrial fibrillation. Q J Med 2007; 100:263–269.
- Therapeutic Guidelines Cardiovascular Writing Group. Therapeutic Guidelines: Cardiovascular, 3rd edition. Melbourne: Therapeutic Guidelines Limited; 1999.
- Kilborn M. Atrial fibrillation. Med J Aust 1999; 170: 498–504.
- Thomas J. Australian Prescriptions Products Guide, 28th edn. Melbourne: Australian Pharmaceutical Publishing Company Limited; 1999.
- PETERSON GM, Boom K, Jackson SL and Vial JH. Doctors’beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Internal Medicine Journal 2002; 32: 15–23.
- Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997; 45: 1060–5.
- Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, et al. Factors Influencing Physicians’Reported Use of Anticoagulation Therapy in Nonvalvular Atrial Fibrillation: A Cross-Sectional Survey. Clinical Therapeutics; 2003:25(6): 1750-1764.
- Lee VWY, Tam CS, Yan BP, Yu CM, Lam YY. Barriers to Warfarin Use for Stroke Preventionin Patients With Atrial Fibrillation in Hong Kong. Clin. Cardiol; 2013:36, 3, 166–171.
Corresponding Author
Dr Amani Alshammari
PMSH
DOI: https://dx.doi.org/10.18535/jmscr/v6i7.59
